Foslevodopa
A prodrug of levodopa used in the treatment of Parkinson's disease
Foslevodopa is a prodrug of levodopa, which is primarily used in the management of Parkinson's disease. It is designed to improve the bioavailability and pharmacokinetic profile of levodopa, thereby enhancing its therapeutic effects and reducing side effects associated with its use.
Pharmacology[edit | edit source]
Foslevodopa is a phosphate ester of levodopa. As a prodrug, it is converted into the active form, levodopa, in the body. This conversion occurs through enzymatic hydrolysis, primarily in the gastrointestinal tract and bloodstream. The primary advantage of foslevodopa over levodopa is its improved solubility and absorption, which can lead to more consistent plasma levels of levodopa.
Mechanism of Action[edit | edit source]
Levodopa, the active form of foslevodopa, is a precursor to the neurotransmitter dopamine. In patients with Parkinson's disease, there is a deficiency of dopamine in the brain, particularly in the striatum. Levodopa crosses the blood-brain barrier and is converted to dopamine by the enzyme aromatic L-amino acid decarboxylase. This increase in dopamine levels helps alleviate the motor symptoms associated with Parkinson's disease, such as bradykinesia, rigidity, and tremor.
Clinical Use[edit | edit source]
Foslevodopa is used in the treatment of Parkinson's disease, particularly in patients who experience fluctuations in response to levodopa therapy. By providing a more stable delivery of levodopa, foslevodopa can help reduce "off" periods and improve overall motor function.
Side Effects[edit | edit source]
The side effects of foslevodopa are similar to those of levodopa, as it is converted to levodopa in the body. Common side effects include nausea, vomiting, dyskinesia, and orthostatic hypotension. Long-term use of levodopa can lead to motor complications such as "wearing-off" phenomena and levodopa-induced dyskinesia.
Development and Approval[edit | edit source]
Foslevodopa is part of ongoing research to improve the treatment of Parkinson's disease. Its development focuses on enhancing the pharmacokinetic properties of levodopa to provide more consistent therapeutic effects and reduce the burden of side effects.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
